tiprankstipranks
Advertisement
Advertisement

DSGN Stock Latest News

Midday Fly By: Dominion to combine with NextEra, Publicis to acquire LiveRamp
The FlyMidday Fly By: Dominion to combine with NextEra, Publicis to acquire LiveRamp
7d ago
D
F
Design Therapeutics reports positive Phase 1/2 DT-216P2 data
PremiumCompany Announcements
Design Therapeutics reports positive Phase 1/2 DT-216P2 data
7d ago
8K
DSGN
Design Therapeutics announces biomarker, clinical data from RESTORE-FA trial
PremiumThe Fly
Design Therapeutics announces biomarker, clinical data from RESTORE-FA trial
7d ago
DSGN
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
PremiumThe Fly
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
13d ago
AZN
BMY
Design Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Design Therapeutics initiated with an Overweight at Cantor Fitzgerald
13d ago
DSGN
Design Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe FlyDesign Therapeutics initiated with an Overweight at Cantor Fitzgerald
13d ago
DSGN
Trump approves plan to fire FDA head Marty Makary, CBS reports
Premium
The Fly
Trump approves plan to fire FDA head Marty Makary, CBS reports
14d ago
DYN
RNA
Design Therapeutics price target raised to $21 from $18 at Oppenheimer
Premium
The Fly
Design Therapeutics price target raised to $21 from $18 at Oppenheimer
21d ago
DSGN
Design Therapeutics price target raised to $20 from $12 at Piper Sandler
PremiumThe Fly
Design Therapeutics price target raised to $20 from $12 at Piper Sandler
26d ago
DSGN
Design Therapeutics reports Q1 EPS (29c), consensus (33c)
PremiumThe Fly
Design Therapeutics reports Q1 EPS (29c), consensus (33c)
27d ago
DSGN
Design Therapeutics Reports Q1 2026 Results and Pipeline Progress
PremiumCompany Announcements
Design Therapeutics Reports Q1 2026 Results and Pipeline Progress
27d ago
8K
DSGN
Design Therapeutics management to meet with Oppenheimer
PremiumThe Fly
Design Therapeutics management to meet with Oppenheimer
1M ago
DSGN
Design Therapeutics management to meet with Oppenheimer
PremiumThe FlyDesign Therapeutics management to meet with Oppenheimer
1M ago
DSGN
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
Premium
The Fly
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
1M ago
DYN
RNA
Design Therapeutics management to meet with Oppenheimer
Premium
The Fly
Design Therapeutics management to meet with Oppenheimer
2M ago
DSGN
Design Therapeutics Appoints David Shapiro to Board
PremiumCompany Announcements
Design Therapeutics Appoints David Shapiro to Board
2M ago
8K
DSGN
Design Therapeutics initiated with a Buy at Jefferies
PremiumThe Fly
Design Therapeutics initiated with a Buy at Jefferies
2M ago
DSGN
Design Therapeutics price target raised to $14 from $13 at RBC Capital
PremiumThe Fly
Design Therapeutics price target raised to $14 from $13 at RBC Capital
3M ago
DSGN
Design Therapeutics reports Q4 EPS (27c), consensus (35c)
PremiumThe Fly
Design Therapeutics reports Q4 EPS (27c), consensus (35c)
3M ago
DSGN
Controversial Prasad leaving FDA, NYT reports
PremiumThe FlyControversial Prasad leaving FDA, NYT reports
3M ago
AZN
BMY
Design Therapeutics announces governance-driven board resignation
Premium
Company Announcements
Design Therapeutics announces governance-driven board resignation
4M ago
8K
DSGN
Design Therapeutics initiated with an Outperform at Oppenheimer
Premium
The Fly
Design Therapeutics initiated with an Outperform at Oppenheimer
5M ago
DSGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >